Report Titled: “Nuclear Imaging Market – Growth, Trends, and Forecast (2019 – 2024)”
The Research Report on “Nuclear Imaging Market” 2019 report includes every aspect of the Nuclear Imaging industry along with the progress performance. Nuclear Imaging Market report presents an analysis of market size, share, and growth, trends, and price structure, statistical and detailed data of the Nuclear Imaging industry. Additionally, Nuclear Imaging Market 2019 research report offers key analysis on the industry status of the Nuclear Imaging producers with market size, growth, share, trends as well as business price structure.
The Nuclear Imaging Market report is a professional and detailed study on the Nuclear Imaging business. Nuclear Imaging market to predict future market directions between the forecast periods from 2019 to 2024 providing you with vital data for your business decisions.
Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999574
Scope of the Report:
Nuclear Imaging Report Also Covers Offer for New Project Includes:
- Market Entry Strategies
- Countermeasures of Economic Impact
- Marketing Channels
- Feasibility Studies of New Project Investment
- Research Conclusions of the Nuclear Imaging Industry
The report provides key statistics on the market status of the Nuclear Imaging Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Nuclear Imaging.
Enquire Before Purchasing this Report – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999574
Nuclear Imaging Market Report Also Covers Marketing Strategy Analysis, Top Manufacturers:
Key Market Trends:
Oncology is Expected to hold its Highest Market Share in PET Applications
In the PET Applications segment, oncology is expected to have the largest market size and is expected to witness a CAGR of 6.35% during the forecast period.
The prevalence of various types of cancer has shown a significant rise over the past two decades. According to the statistics of Lymphoma Research Foundation, each year, more than 100,000 people are diagnosed with lymphoma, and nearly one million people in the United States are living with, or are in remission from, lymphoma. It is the third-most common cancer in children. According to the Global Burden of Disease – 2013 study, 725,000 people had Hodgkin’s lymphoma, and 24,000 died due to this, in 2013. 2.96 million people had non-Hodgkin’s lymphoma, and 226,000 died due to this, in 2013.
The FDG-PET/CT is more sensitive than contrast-enhanced CT scan in the staging of several types of lymphoma or in detecting tumor dissemination in several solid cancers, such as breast cancer, lung cancer, and colon cancer.
In the field of oncology, the PET (positron emission tomography) uses FDG (18Fluorine-2-fluoro-2-Deoxy-d-glucose) as the radiopharmaceutical, as it demonstrates the increased metabolism by malignant cells, when compared to that of normal cells. Furthermore, there is continuous technological progress in the field of image generation. The introduction of sophisticated software to use PET scan as a biomarker has facilitated new ways to calculate new prognostic markers, such as the metabolic tumor volume (MTV) and the total amount of tumor glycolysis (TLG). The 18F-fluorodeoxyglucose (18F-FDG) has high sensitivity, but it is not tumor specific. This technique can be used for the imaging of lung cancer, lymphoma, head and neck tumors, breast cancer, esophageal cancer, colorectal cancer, and urinary tract tumors. Hence, all the aforementioned technological advancements are expected to drive growth in this segment of the market studied, over the forecast period.
North America Domainates the Market and is Expected to do the Same in the Forecast Period
North America is projected to account for the largest share of the market, due to the advancements in technology, including hybrid imaging, the introduction of new radiopharmaceuticals for diagnosis, and the development of molecular imaging.
In 2016, the AMIPA (American Medical Isotope Production Act) and the DOE/NNSA (Department of Energy) established a Uranium Lease and Take-Back (ULTB) program in the United States. Under this program, the DOE/NNSA makes LEU (Low Enriched Uranium) available through lease contracts for the irradiation and production of Mo99 for medical uses. The AMIPA not only promotes the domestic production of Mo-99, but also aims to replace the role of HEU (High Enriched Uranium) in the production of medical radioactive isotopes.
Moreover, Canada is one of the largest producers of Technetium-99m. With the use of Tc-99m in radiopharmaceuticals, the market is expected to grow at a tremendous rate in Canada. It is also combined with a variety of biologically active molecules to perform non-invasive, real-time imaging of the human body.
Furthermore, there has been increasing awareness among people in this region about nuclear medicine treatment and diagnosis, which, in turn, has increased the prescriptions by physicians. This is expected to trigger the growth of the market.
Purchase this Report (Price 4250 USD for Single User License) – https://www.industryresearch.co/purchase/13999574
Detailed TOC of Nuclear Imaging Market Report are:
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Prevalence of Cancer and Cardiac Disorders
4.2.2 Increase in Technological Advancements
4.2.3 Growth in Applications of Nuclear Medicine and Imaging
4.3 Market Restraints
4.3.1 Regulatory Issues
4.3.2 Lack of Reimbursement
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 By Equipment
5.1.2 By Radioisotope
184.108.40.206 By Diagnostic Technology
220.127.116.11.1 SPECT Radioisotopes
18.104.22.168.1.1 Technetium-99m (TC-99m)
22.214.171.124.1.2 Thallium-201 (TI-201)
126.96.36.199.1.3 GalliumÂ (Ga-67)
188.8.131.52.1.4 Iodine (I-123)
184.108.40.206.1.5 Other SPECT Radioisotopes
220.127.116.11.2 PET Radioisotopes
18.104.22.168.2.1 Fluorine-18 (F-18)
22.214.171.124.2.2 Rubidium-82 (RB-82)
126.96.36.199.2.3 Other PET Radioisotopes
5.2 By Application
5.2.1 SPECT Applications
188.8.131.52 Other SPECT Applications
5.2.2 PET Applications
184.108.40.206 Other PET Applications
5.3.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
5.3.4 Middle East & Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle East & Africa
5.3.5 South America
18.104.22.168 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bracco Imaging SpA
6.1.2 Cardinal Health Inc.
6.1.3 GE Healthcare
6.1.4 Koninklijke Philips NV
6.1.5 Siemens Healthineers
6.1.7 CMR NAVISCAN (GAMMA MEDICA INC.)
6.1.8 Nordion (Canada) Inc.
6.1.9 NTP Radioisotopes SOC
6.1.10 Toshiba Medical Systems Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Name: Ajay More
Phone: US +14242530807/ UK +44 20 3239 8187
Email: [email protected]
Our Other Reports: